Lilly
1Q Revenues: $8.8 billion (+26%)
1Q Earnings: $2.2 billion (+67%) 
Comments: Growth in the quarter was driven by Mounjaro, Zepbound, Verzenio and Jardiance, partially offset by declines in Trulicity. Demand for the company’s incretin medicines outpaced supply increases. The company continues to expand manufacturing capacity, with the most significant production increases in 2024 expected in the second half of the year. Mounjaro sales were $1.8 billion in the quarter, compared to $568.5 million 1Q23. Verzenio sales were up 40% to $1.05 billion. Zepbound sales contributed $517.4 million in the quarter. Jardiance sales were $686.5 million, up 19%. Trulicity sales were down 26% to $1.45 million, primarily due to supply constraints and competitive dynamics. Taltz revenue increased 15% to $604.1 million. Humalog revenue increased 17% to $538.7 million.